Sermorelin
Sermorelin is a synthetic peptide corresponding to growth hormone–releasing hormone GHRH(1–29) amide (GRF(1–29)NH₂), the bioactive fragment that engages the GHRH receptor on pituitary somatotrophs. In research models it elicits short-acting, pulse-like growth hormone (GH) release and downstream IGF-1 signaling, enabling precise studies of somatotropic axis dynamics and feedback regulation.
Batch Details: SERM5-A1
Sermorelin is a research-grade analogue of endogenous GHRH comprising the first 29 amino acids with a C-terminal amide for enhanced stability. Its rapid pharmacokinetic profile preserves physiological pulsatility of GH secretion, making it a versatile tool for time-resolved endocrine experiments and comparative studies with other secretagogues.
Research SignificanceDirect activation of pituitary GHRH receptors to stimulate GH and modulate IGF-1Short duration of action ideal for modeling physiological GH pulsatility and feedback (somatostatin/GH autoregulation)Useful probe for hypothalamic–pituitary–somatotropic axis sensitivity and desensitizationCompatible with combination studies alongside ghrelin receptor agonists to assess synergistic secretagogue effects
Potential Research ApplicationsEndocrine pathway mapping of GH/IGF-1 signaling and target-tissue transcriptional responsesMetabolic investigations of lipid, glucose, and protein turnover downstream of GHBody composition and tissue remodeling models (lean mass/adiposity endpoints)Chronobiology and dosing-schedule studies requiring precise temporal control of GH pulses
SpecificationsForm: Lyophilized peptide powderContent: SermorelinIdentity: GHRH(1–29) amide (GRF(1–29)NH₂)Storage: Store at −20 °C; once reconstituted, use promptly under sterile lab conditions
